CLINICAL TRIALS PROFILE FOR GTX-024
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Clinical Trials for GTx-024
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00020735 ↗ | Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using toremifene may fight prostate cancer by reducing the production of androgens. PURPOSE: Randomized phase II trial to study the effectiveness of toremifene followed by radical prostatectomy in treating patients who have stage I or stage II prostate cancer. |
| NCT00020735 ↗ | Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer | Completed | Joel Nelson, MD | Phase 2 | RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using toremifene may fight prostate cancer by reducing the production of androgens. PURPOSE: Randomized phase II trial to study the effectiveness of toremifene followed by radical prostatectomy in treating patients who have stage I or stage II prostate cancer. |
| NCT00119314 ↗ | Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin | Withdrawn | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Drugs used in chemotherapy, such as gemcitabine, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel and capecitabine works in treating patients with cancer of unknown primary origin. |
| NCT00119314 ↗ | Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin | Withdrawn | University of Medicine and Dentistry of New Jersey | Phase 2 | RATIONALE: Drugs used in chemotherapy, such as gemcitabine, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel and capecitabine works in treating patients with cancer of unknown primary origin. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for GTx-024
Condition Name
Clinical Trial Locations for GTx-024
Trials by Country
Clinical Trial Progress for GTx-024
Clinical Trial Phase
Clinical Trial Sponsors for GTx-024
Sponsor Name
